6 views 0 likes

StayCurrentMD

GCMD Space · View profile →

Characteristics of Transfusion and Association With Oncologic Outcomes in Hepatoblastoma Resection

Video Published 2026-04-10 Updated 2026-08-01

Timestops (3)

Topic Overview

A single-speaker summary of a 2025 multi-institutional study published in Pediatric Blood and Cancer examining the relationship between intraoperative transfusion and oncologic outcomes in hepatoblastoma resection. The study found that while transfusion did not affect recurrence, it was associated with increased mortality. The authors identified instances of unnecessary transfusion and postoperative coagulopathy, recommending more selective transfusion practices and balanced transfusion protocols.

Key Takeaways

  • Intraoperative transfusion in hepatoblastoma resection associated with increased mortality but not recurrence. (0:32)
  • RBC-predominant transfusion may contribute to postoperative coagulopathy requiring additional plasma and platelets. (0:25)
  • Unnecessary transfusions occurred; more selective patient selection and balanced transfusion protocols recommended. (0:39)

Inside this episode

Kai, the Library's AI content creator, listened to this episode and mapped who's speaking, the chapters, key claims, and cases. Every item links to the exact moment in the recording.

AI-enriched

Who's speaking

  • Jill Kneroth — host

Chapters

  • 0:00Introduction and Study Context — Introduction to the clinical question of whether intraoperative transfusion during hepatoblastoma resection affects oncologic outcomes, and identification of the source study.
  • 0:24Study Findings — Key results including transfusion patterns, effects on recurrence and mortality, and evidence of unnecessary transfusions and postoperative complications.
  • 0:51Author Recommendations — Authors' interpretation linking red blood cell-predominant transfusion to coagulopathy and recommendations for improved transfusion practice.

Key claims

  • 0:00It is not uncommon for a patient with hepatoblastoma to need a transfusion during resection — Jill Kneroth
  • 0:13The study was multi-institutional and published in Pediatric Blood and Cancer in 2025 — Jill Kneroth
  • 0:19The study examined how intraoperative transfusion may affect recurrence and survival in hepatoblastoma resection patients — Jill Kneroth
  • 0:25Of those transfused, the majority received red blood cells — Jill Kneroth
  • 0:25Only 11% of transfused patients received platelets — Jill Kneroth
  • 0:32Intraoperative blood transfusions had no effect on recurrence — Jill Kneroth
  • 0:32Intraoperative blood transfusions were associated with increased death — Jill Kneroth
  • 0:39There were instances of unnecessary blood transfusions — Jill Kneroth
  • 0:43Patients who were transfused had higher post-op hemoglobin — Jill Kneroth
  • 0:43Transfused patients still required more plasma and platelets postoperatively — Jill Kneroth
  • 0:52The authors think that blood transfusions were mostly red blood cells, and that is what contributed to the post-op coagulopathy — Jill Kneroth
  • 1:00The authors recommend more careful patient selection for intraoperative transfusions — Jill Kneroth
  • 1:00The authors recommend a balanced transfusion approach — Jill Kneroth

Open questions

  • Does this change the way you see intraoperative transfusions?
This episode was analyzed and enriched by Kai, the Library's AI content creator. Every item links to the moment it comes from — click a timestamp to listen in context.
Written for:

Rethinking Transfusion Strategy in Pediatric Liver Tumor Resection

The episode's main topic retold as a plain-language walkthrough — what it is, why it matters, and what the speakers concluded. Written by Kai from the episode transcript and reviewed before publishing.

For the care team · Explainer · AI-written, human-reviewed

Why This Matters

Hepatoblastoma is the most common primary liver malignancy in children, typically presenting before age three 0:13. Resection after neoadjuvant chemotherapy is curative in most cases 0:13, but the operations are technically demanding—these tumors are vascular, the liver parenchyma in young children is small and unforgiving, and blood loss can be substantial relative to circulating volume. Transfusion during these cases is common 0:00. Until recently, the question of whether intraoperative transfusion affects oncologic outcomes—recurrence, survival—had not been systematically examined in this population 0:13.

The Core Clinical Problem

A multi-institutional study published in *Pediatric Blood and Cancer* in 2025 examined the relationship between intraoperative transfusion and outcomes in children undergoing hepatoblastoma resection 0:13 0:19. The findings challenge the assumption that transfusion is a neutral supportive intervention. While intraoperative transfusion had no effect on tumor recurrence 0:32, it was associated with increased mortality 0:32. That association alone does not prove causation—sicker patients and more difficult resections require more blood—but the transfusion patterns revealed a practice problem that may be modifiable 0:39 0:52.

What the Data Show

Among patients who received intraoperative transfusion, the majority received red blood cells, but only 11% received platelets 0:25 0:25. This is RBC-predominant transfusion in a setting where coagulopathy is mechanistically likely. The study identified instances of unnecessary transfusion 0:39—patients whose post-resection hemoglobin levels were higher than clinical need would justify 0:43. More telling: those same patients required more plasma and platelets postoperatively 0:43, suggesting that the intraoperative transfusion strategy created or worsened a coagulopathy rather than preventing one 0:52.

The authors interpret this as evidence that red blood cell transfusion without concurrent plasma and platelet support contributed to postoperative coagulopathy 0:52. In trauma and adult hepatobiliary surgery, unbalanced transfusion—RBCs without proportional plasma and platelets—is known to worsen outcomes by diluting clotting factors and inducing consumptive coagulopathy. The hepatoblastoma data suggest the same mechanism operates in pediatric oncologic liver resection 0:52.

The Proposed Solution

The authors recommend two changes in practice 1:00 1:00. First, more careful patient selection for intraoperative transfusion—reserving it for patients with genuine physiologic need rather than reflexive administration at arbitrary hemoglobin thresholds 1:00. Second, when transfusion is indicated, a balanced approach: red cells, plasma, and platelets in ratios that preserve coagulation function rather than dismantling it 1:00.

Balanced transfusion is not a new concept 1:00, but its application in pediatric solid tumor surgery has lagged behind trauma and cardiac surgery, where massive transfusion protocols are standard. The hepatoblastoma study provides pediatric-specific evidence that unbalanced transfusion is not benign and that the principles proven in other high-blood-loss settings apply here 0:52 1:00.

What Remains Uncertain

The study does not establish a causal mechanism linking transfusion to mortality 0:32. The association could reflect unmeasured confounders—tumor biology, extent of resection, surgeon experience, or perioperative complications that both necessitate transfusion and independently increase mortality risk. The study also does not provide specific transfusion thresholds or ratios 1:00 1:00, leaving the definition of "balanced" and "necessary" to institutional judgment.

Whether restrictive transfusion strategies—tolerating lower intraoperative hemoglobin—are safe in this population is not addressed. Pediatric patients undergoing chemotherapy may have baseline marrow suppression, and the oxygen-carrying capacity required during a major hepatic resection in a small child is not the same as in an adult or a trauma patient.

When to Involve Pediatric Surgical Oncology

Hepatoblastoma is managed by pediatric surgical oncologists in coordination with pediatric oncology and, in complex cases, transplant hepatology 0:13. Referral should occur at diagnosis. Any child with a liver mass and elevated alpha-fetoprotein should be discussed with a center experienced in pediatric liver tumors before biopsy—these tumors are often resectable after chemotherapy 0:13, and biopsy can cause tumor rupture or seeding. Timing of resection is determined by tumor response to chemotherapy 0:13, and the decision to proceed with resection versus transplant depends on the extent of liver involvement and vascular invasion.

For the anesthesiologist or intensivist managing these patients perioperatively, the key takeaway is that transfusion strategy matters 0:52 1:00 1:00. If transfusion is required, it should be balanced from the outset, not corrected afterward 1:00. If a patient's hemoglobin is adequate and they are hemodynamically stable, transfusion may be unnecessary regardless of arbitrary triggers 1:00. The goal is to finish the operation with a functioning coagulation system, not just a normal hemoglobin 0:52 1:00.

Takeaways from this story

  • Intraoperative transfusion in hepatoblastoma resection was associated with increased mortality but not recurrence.
  • Most transfused patients received only red cells; only 11% received platelets, contributing to postoperative coagulopathy.
  • Balanced transfusion—red cells with plasma and platelets—may prevent coagulopathy better than RBC-only strategies.
  • Some transfusions were unnecessary: transfused patients had higher post-op hemoglobin than clinical need justified.

Keywords

Hashtags

Transcript

Comments

Loading comments…